The mTOR pathway is in the process of establishing itself as a key access-point of novel\noncological drugs and targeted therapies. This is also reflected by the growing number of mTOR\npathway genes included in commercially available next-generation sequencing (NGS) oncology\npanels. This review summarizes the portfolio of medium sized diagnostic, as well as research\ndestined NGS panels and their coverage of the mTOR pathway, including 16 DNA-based panels\nand the current gene list of Foundation One as a major reference entity. In addition, we give an\noverview of interesting, mTOR-associated somatic mutations that are not yet incorporated.\nEspecially eukaryotic translation initiation factors (eIFs), a group of mTOR downstream proteins,\nare on the rise as far as diagnostics and drug targeting in precision medicine are concerned. This\nreview aims to raise awareness for the true coverage of NGS panels, which should be valuable in\nselecting the ideal platform for diagnostics and research.
Loading....